HighTower Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.3M Sell
49,020
-16,664
-25% -$7.39M 0.02% 585
2026
Q1
$29.3M Buy
65,684
+18,125
+38% +$8.45M 0.03% 498
2025
Q4
$21.6M Buy
47,559
+3,544
+8% +$1.53M 0.02% 584
2025
Q3
$17.2M Sell
44,015
-12,332
-22% -$5.15M 0.02% 647
2025
Q2
$25.1M Buy
56,347
+2,722
+5% +$1.25M 0.03% 502
2025
Q1
$26M Buy
53,625
+5,039
+10% +$2.35M 0.04% 463
2024
Q4
$19.6M Sell
48,586
-8,656
-15% -$4.01M 0.03% 534
2024
Q3
$26.5M Buy
57,242
+4,148
+8% +$1.99M 0.04% 441
2024
Q2
$24.7M Sell
53,094
-4,192
-7% -$1.82M 0.04% 438
2024
Q1
$24M Sell
57,286
-25,163
-31% -$10.6M 0.04% 426
2023
Q4
$33.4M Sell
82,449
-6,045
-7% -$2.23M 0.06% 334
2023
Q3
$30.7M Buy
88,494
+4,553
+5% +$1.59M 0.06% 325
2023
Q2
$29.5M Buy
83,941
+22,918
+38% +$7.72M 0.06% 325
2023
Q1
$19.3M Sell
61,023
-2,805
-4% -$841K 0.04% 415
2022
Q4
$18.4M Buy
63,828
+13,869
+28% +$4.23M 0.04% 420
2022
Q3
$14.5M Sell
49,959
-7,848
-14% -$2.26M 0.04% 439
2022
Q2
$16.3M Sell
57,807
-36,502
-39% -$9.77M 0.04% 406
2022
Q1
$24.6M Buy
94,309
+29,446
+45% +$6.99M 0.05% 324
2021
Q4
$14.2M Buy
64,863
+11,205
+21% +$2.18M 0.03% 482
2021
Q3
$9.69M Buy
53,658
+40,274
+301% +$7.86M 0.03% 544
2021
Q2
$2.69M Sell
13,384
-2,251
-14% -$471K 0.01% 1068
2021
Q1
$3.36M Buy
+15,635
New +$3.43M 0.01% 883
2020
Q4
Sell
-13,185
Closed -$3.59M 2873
2020
Q3
$3.59M Buy
13,185
+1,806
+16% +$498K 0.02% 668
2020
Q2
$3.31M Buy
11,379
+1,410
+14% +$382K 0.02% 643
2020
Q1
$2.38M Sell
9,969
-193
-2% -$44.3K 0.02% 693
2019
Q4
$2.23M Buy
10,162
+1,502
+17% +$304K 0.01% 816
2019
Q3
$1.47M Buy
8,660
+1,958
+29% +$346K 0.01% 1001
2019
Q2
$1.23M Buy
6,702
+1,170
+21% +$205K 0.01% 1095
2019
Q1
$1.01M Sell
5,532
-1,366
-20% -$252K 0.01% 1134
2018
Q4
$1.14M Sell
6,898
-3,383
-33% -$586K 0.01% 991
2018
Q3
$1.99M Buy
10,281
+3,297
+47% +$587K 0.01% 838
2018
Q2
$1.19M Buy
6,984
+274
+4% +$42.5K 0.01% 1049
2018
Q1
$1.09M Sell
6,710
-1,346
-17% -$220K 0.01% 1034
2017
Q4
$1.2M Sell
8,056
-7,931
-50% -$1.17M 0.01% 1018
2017
Q3
$2.43M Sell
15,987
-2,988
-16% -$450K 0.02% 754
2017
Q2
$2.45M Buy
18,975
+588
+3% +$70.8K 0.02% 725
2017
Q1
$2.01M Buy
18,387
+11,669
+174% +$1.03M 0.02% 757
2016
Q4
$495K Sell
6,718
-1,836
-21% -$149K 0.01% 1257
2016
Q3
$748K Buy
8,554
+5,660
+196% +$535K 0.01% 1045
2016
Q2
$252K Sell
2,894
-3,826
-57% -$331K ﹤0.01% 1392
2016
Q1
$532K Sell
6,720
-4,348
-39% -$393K ﹤0.01% 1347
2015
Q4
$1.4M Buy
11,068
+7,514
+211% +$907K 0.02% 789
2015
Q3
$369K Sell
3,554
-4,173
-54% -$536K ﹤0.01% 1354
2015
Q2
$954K Sell
7,727
-14,894
-66% -$1.88M 0.02% 775
2015
Q1
$2.67M Sell
22,621
-8,836
-28% -$1.06M 0.04% 495
2014
Q4
$3.74M Sell
31,457
-25,550
-45% -$2.88M 0.06% 357
2014
Q3
$6.4M Sell
57,007
-1,873
-3% -$178K 0.11% 222
2014
Q2
$5.58M Buy
58,880
+331
+0.6% +$23.2K 0.1% 230
2014
Q1
$4.14M Buy
58,549
+52,796
+918% +$4.18M 0.08% 287
2013
Q4
$427K Buy
5,753
+1,155
+25% +$80.4K 0.01% 1023
2013
Q3
$349K Buy
4,598
+554
+14% +$44.1K 0.01% 972
2013
Q2
$324K Buy
+4,044
New +$298K 0.01% 960

Other funds holding VRTX

HighTower Advisors's VRTX Position: Q2 2026 in Review

HighTower Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, selling an estimated $7.39M and leaving 49,020 shares worth $24.3M. The position accounts for 0.02% of the portfolio, ranked #585.

HighTower Advisors first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.4M in Q4 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HighTower Advisors held 49,020 shares of Vertex Pharmaceuticals worth $24.3M as of Q2 2026.
  • HighTower Advisors sold 16,664 Vertex Pharmaceuticals shares in Q2 2026, an estimated $7.39M.
  • Vertex Pharmaceuticals made up 0.02% of HighTower Advisors's portfolio in Q2 2026, its #585 holding.
  • HighTower Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • HighTower Advisors's Vertex Pharmaceuticals position peaked at $33.4M in Q4 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.